LUM GmbH has recently entered into a strategic partnership with Alpharmaca Inc., a Shanghai-based company, to meet the increasing demand from the pharmaceutical and semiconductor sectors. This collaboration aims to enhance local expertise in particle characterization and materials testing.
Founded in 2010, Alpharmaca serves as a resource platform for China's industrial 4.0 transformation, introducing advanced technologies and products from around the world. The company focuses on nanotechnology within the pharmaceutical industry while covering various sectors, including biotechnology, chemicals, and semiconductors.
Susanne Lerche-Merchant, CEO of LUM GmbH, expressed enthusiasm for the partnership, stating, “This collaboration strengthens our market presence in crucial future industries, benefiting both current and prospective customers.” The LUMiSpoc single particle counter will provide solutions for particle counting and size distribution, essential in the pharmaceutical sector, including applications in COVID-19 vaccine development.
In addition to pharmaceuticals, the semiconductor industry relies heavily on grinding and polishing pastes, where precise particle characterization and stability assessment are critical. LUM's technologies will soon be utilized in Alpharmaca's application laboratory, offering customers varied insights into their samples.
This partnership marks a significant step in LUM's ongoing international strategy, aiming to address the needs of dynamic industries.